Sorbitol is an intermediate in the polyol pathway, which converts from glucose to fructose by sorbitol dehydrogenase (SORD). Androgens are essential for the development of prostate cancer. We studied castration-induced gene expression changes in the human prostate using the GeneChip array, and identified SORD as being androgen-regulated in the human prostate. A putative androgen-responsive regulatory region at the SORD 5' promoter was identified using promoter deletion constructs in a luciferase reporter assay in COS-7 cells. Chromatin immunoprecipitation assay was used to assess the binding of androgen receptor to suggested androgen responsive regulatory region. Finally, the expression of SORD in the human prostate was evaluated in 29 prostate tissue samples by immunohistochemistry. The expression of SORD decreased after castration. Androgen supplementation to the LNCaP prostate cancer cell line led to a 7.5-fold increase in SORD mRNA expression. Furthermore, a chromatin immunoprecipitation assay proved that the androgen receptor can bind to this putative androgen-responsive regulatory region. Finally, the expression of SORD in the human prostate was localised to epithelial cells of both benign and malignant prostate tissue by immunohistochemistry. In prostate cancer, increased immunostaining was associated with high Gleason patterns and high serum prostate-specific antigen concentrations. These results show that SORD is a novel androgen-regulated gene in the human prostate and suggest the need for more detailed analysis of the physiological role of SORD in the prostate.
Introduction
Sorbitol dehydrogenase (SORD) catalyses the interconversion of polyols and their corresponding ketoses. SORD deficiency has been linked with congenital cataracts (1) . SORD expression is high in the human kidney and lens of the eye (2) and widely expressed in other human tissues as well (3) . The clinical significance of SORD has been evaluated mainly with a focus on the complications of diabetes (4) . In humans, SORD is secreted by the epididymal epithelium. This supports the suggestion that the polyol pathway plays a role in human sperm physiology (5) . Androgens are a prerequisite for the development of prostate cancer, which is the most common malignancy of men in the western world. Androgen ablation triggers cell death or cell cycle arrest of prostate cancer cells (6) . The action of androgens on gene expression is mediated via the androgen receptor (AR) (7) . The AR belongs to a superfamily of nuclear receptors that function as ligand-activated transcription factors. The AR is a type 1 receptor that forms homodimers after ligand binding and binds inverted repeattype DNA response elements in the regulatory regions of the target genes (8) .
Here, we used a GeneChip array to search for novel genes regulated by androgens in the human prostate. SORD was identified as being down-regulated by castration, indicating androgen-dependent expression. SORD androgen induction was also detected in the prostate-derived cell line LNCaP. We studied the expression and tissue localisation of SORD protein in the prostate. SORD immunostaining was detected in epithelial cells with increased staining intensity in samples with high Gleason patterns and high serum prostate-specific antigen (PSA) concentrations. We studied the mechanism of SORD regulation by androgens and present evidence showing that androgens may regulate SORD by the classical ARmediated mechanism, as the AR binds to the SORD 5' regulatory region. These results establish SORD as a novel androgenregulated enzyme in the human prostate with increased immunostaining in poorly differentiated prostate carcinomas.
Materials and methods
Patient samples and GeneChip protocol. Sample collection, preparation and GeneChip procedures have been described in detail elsewhere (9) . Briefly, androgen-regulated genes in the human prostate were studied using prostate biopsy samples taken three days after surgical castration performed for the treatment of prostate cancer. RNA from 6 patient samples was individually labelled and used for the GeneChip array. Three samples were histologically confirmed as benign prostate tissue from radical prostatectomy specimens and 3 samples were from biopsies taken after surgical castration performed as a therapeutic procedure for prostate cancer. The expression profiles were analysed using Chipster software (http://chipster. csc.fi). All GeneChips were normalised using the RMA (robust multiarray average) method and gene expression intensity estimates were received in log2-transformed values. The archived prostate specimens were initially collected from patients that underwent prostatectomy or transurethral resection of the prostate for the treatment of prostate cancer or benign prostatic hyperplasia (BPH) at the Oulu University Hospital. The material consisted of 25 prostate cancer and four BPH tissue specimens. There were 12, 4 and 9 prostate cancer samples from radical prostatectomy, transurethral resection for symptoms of BPH (occult carcinoma) and palliative transurethral resections of prostate cancer patients with castration therapy ongoing, respectively. Different Gleason patterns were selected for the multitissue block. There were 6, 7, 6 and 6 samples with Gleason pattern 2, 3, 4 and 5, respectively, and 4 BPH samples. Gleason patterns were used in statistical analyses instead of the Gleason scores because the specific patterns were selected for the multitissue block. Information about the corresponding PSA concentrations preceding tissue sampling were obtained from patient records. The PSA concentrations preceding tissue sampling varied from 2.9 to 262 ng/ml for cases present at the multitissue block. Informed consent was obtained from every subject before fresh tissue sampling. The ethics council of the Northern Ostrobothnia Hospital District approved the protocol.
Cell culture. Prostate cancer cell line LNCaP (CRL-1740) cells and African green monkey kidney fibroblast-like cell line COS-7 (CRL-1651) cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). LNCaP and COS-7 cell cultures were maintained in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 2.5 g/l D-glucose or DMEM (Sigma-Aldrich) supplemented with 4500 mg/l glucose, L-glutamine and 1% penicillinstreptomycin (Invitrogen-Gibco, Carlsbad, CA, USA), respectively, and were added to 10% fetal bovine serum (HyClone, Logan, UT, USA) at 37˚C in a humidified atmosphere of 5% CO 2 . Fetal bovine serum was substituted with charcoaltreated fetal bovine serum in the hormone-induction experiments. Seventy-two hours prior to experiments the LNCaP cells were plated with 1x10 6 cells per plate. Cells were treated with 10 nM synthetic androgen R1881 (Perkin-Elmer, Boston, MA, USA) or an equal volume of ethanol for 0, 6, 24 or 48 h. After incubation, cells were harvested, washed with phosphatebuffered saline and used directly for isolation of RNA. For transfection, COS-7 cells were grown to 80% confluency before transfection.
Plasmids. The SORD (GenBank accession no. NM_003104.4) promoter fragments were cloned into pGL3-Basic (Promega, Madison, WI, USA) upstream of the luciferase reporter gene at the HindIII and SacI sites. A genomic clone (rzpdb737b102039d) was purchased from imaGenes (www.
imagenes-bio.de) for use as a template for PCR with oligonucleotides 5'-GTACAAGCTTGGACGTTTGGTCGCT CTG-3' and 5'-CGAAGAGCTCTGCCCAGTTCAACCT TCC-3' containing HindIII and SacI digestion site sequences, respectively, at their 5'-ends to clone the SORD 5' upstream promoter region starting from position -2391 to +101 (positions numbered from the transcription initiation start site). This region corresponds to nucleotides 45312950-45315442 in NC_000015.9 (NCBI reference sequence). Deletion constructs were created respectively using oligonucleotides 5'-CGAAG AGCTCTGGTGTGCCATTTGCTAAGA-3', 5'-CGAAGAG CTCTAGGTAATCAAGCGGGCAAG-3' and 5'-CGAAGA GCTCGTAGCACCAACCAGATT-3' for the creation of 5' upstream deletion constructs -2230, -1843 or -1699 to +101, respectively. All clones were sequenced to exclude mutations and deletions during cloning. Potential androgen response elements (AREs) were identified using the TESS (Transcription Element Search System) programme (http://www. cbil.upenn.edu/cgi-bin/tess/tess).
Transfections. The COS-7 cells were seeded into 24-well plates at 30000 cells per well 24 h before transfection. The cells were transfected with Dotap transfection reagent (Roche Diagnostics GmbH, Penzberg, Germany) according to the manufacturer's protocol, using 0.65 μg of plasmid and 3 μg of transfection reagent and DMEM media (Sigma-Aldrich). AR cDNA in pcDNA3.1 vector (a gift from Professor T. Visakorpi, University of Tampere, Tampere, Finland) was cotransfected. Twenty-four hours after transfection, the media was replaced with DMEM and 100 nM R1881 (Perkin-Elmer) was added when appropriate for 48 h. To provide an internal control for transfection efficiency, a second reporter plasmid pRL-TK (Promega) was transfected. The luciferase activities for COS-7 cells were measured using the Dual-luciferase reporter assay system (Promega). Mouse mammary tumour virus promoter in pGL3-Basic (a gift from Professor J. Palvimo, University of Kuopio, Kuopio, Finland) was used as a control for androgen response.
Quantitative reverse transcription-polymerase chain reaction.
Total RNA from LNCaP cells was isolated with TRIzol reagent (Invitrogen-Gibco) for quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) measurements, according to the manufacturer's protocol. RNA isolated from prostate samples was also used. The first-strand cDNA was synthesized with the First-Strand cDNA synthesis kit (Amersham Biosciences, Piscataway, NJ, USA) using 1 μg of RNA and pd(N)6 random hex deoxynucleotides according to the manufacturer's instructions. mRNA levels for LNCaP cells and human prostate samples were measured by quantitative RT-PCR analysis (ABI 7700, Applied Biosystems, Foster City, CA, USA) as described previously (10) . Forward and reverse primers for SORD mRNA detection were 5'-TGAGA TGACCACCGTACCCC-3' and 5'-GAAACACGCCCTTG ATATCCA-3', respectively. The amplicon was detected using fluorogenic probe 5'-FAM-TGCATGCAGCCATCCGG GAG-TAMRA-3'. The primers and the probe for the 18S amplicon were 5'-TGGTTGCAAAGCTGAAACTTAAAG-3', 5'-AGTCAAATTAAGCCGCAGGC-3' and 5'-VIC-CCTGG TGGTGCCCTTCCGTCA-TAMRA-3', respectively.
Immunochemistry. Proteins from snap-frozen prostate tissue were isolated using RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) as described (11) . After boiling the samples in reducing SDS sample buffer for 5 min, 10 μg of protein was loaded per lane and the samples were electrophoresed on 10% polyacrylamide SDS gel and transferred to a PVDF membrane. SORD was detected with SORD monoclonal antibody (M01, clone 4D3, catalogue no. H00006652-M01, Abnova, Taipei City, Taiwan, dilution 1:10000). For negative control, a 10-fold excess of SORD recombinant protein (H00006652-Q01, Abnova) was incubated with antibody overnight at 4˚C before detection. Binding of target proteins on the membranes was revealed with goat anti-mouse HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The protein bands were visualised by chemiluminescence.
Multitissue block slides containing 4 μm sections of formalin-fixed, paraffin-embedded prostate samples were used for immunohistochemistry. The sections were then routinely deparaffinised in xylene and rehydrated in descending ethanol series. To enhance immunoreactivity, the sections were incubated in a citrate buffer (pH 6.0) and boiled. Endogenous peroxidase activity was eliminated by incubation in hydrogen peroxide and absolute methanol. SORD monoclonal antibody (M01, clone 4D3, Abnova, dilution 1:7000) was used. The Envision-kit (Dako, Glostrup, Denmark) was used for visualisation. The immunostainings were classified as negative, weakly positive or strongly positive. Using these criteria, the immunostaining results were evaluated by two observers (P.H. and M.H.V.) and a consensus was reached.
Chromatin immunoprecipitation (ChIP) . ChIP was carried out in the conditions described previously (12) using a commercially available SimpleChIP kit (Cell Signaling Technology, Danvers, MA, USA). Androgen receptor antibody PG-21 (catalogue no. 06-680, Millipore, Temecula, CA, USA) was used in the immunoprecipitation reaction. The input genomic DNA samples were treated in the same way except that no immunoprecipitation was performed. Primers 5'-CCTATTTGGCCATCTTGGAA-3' and 5'-CTTGCCCGC TTGATTACCTA-3' were used in PCR reactions to amplify the region of the predicted androgen receptor binding site at the SORD promoter. To achieve linear amplification ranges, immunoprecipitated and input products were amplified with 40 and 36 cycles, respectively.
Statistical analyses. Student's t-test was used for comparison between two groups and the difference was considered to be statistically significant when the P-value was <0.05. The immunostaining quantification results were analyzed using SPSS for Windows 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Androgen regulation of SORD mRNA in human prostate tissue and the LNCaP prostate cancer cell line. In an attempt to find novel androgen-regulated genes in the human prostate, we analysed relative gene expression levels in benign prostate tissue samples and in prostate samples taken after castration using a GeneChip array. Normalised log2-transformed expression values of SORD mRNA (Affymetrix cell ID: 201563_at) in three benign prostate tissue samples and three prostate samples taken after castration were 10.53, 9.81, 10.84, 8.12, 8.02 and 8.10, respectively. This provided a 2.31-fold change in expression when comparing the three benign prostate tissue samples to the three castrated prostate tissue samples. The normalised log2-transformed expression values of SORD and some known androgen-regulated genes and prostate cancer associated genes identified here are presented in Table I. SORD expression and androgen regulation were then analysed in the LNCaP cell line using quantitative RT-PCR. A 7.5-fold increase in SORD mRNA expression was detected after 48 h of treatment with 10 nM R1881 (Fig. 1) . Table I . GeneChip array results of some known androgen-regulated genes, prostate cancer associated genes and SORD in three castrated samples and in three benign prostate samples.
Dipeptidyl-peptidase 4 (CD26) 6.53 6.07 6 
Normalized, log2-transformed expression values are presented. Fold expression change was calculated from means of log2-transformed expression values between castrated samples and benign prostate samples.
Identification of region for putative androgen receptor binding in SORD promoter.
To study the involvement of transcriptional regulation in the regulation of SORD by androgens and to locate the putative androgen-responsive regulatory region, a series of constructs containing the SORD promoter region starting from positions -2391, -2230, -1843 or -1699 to +101 (positions numbered from the transcription initiation start site) were transfected into COS-7 cells together with an AR expression vector and the cells were treated with androgen or vehicle only. The results for transient transfections are shown in Fig. 2 . Androgen induction was detected for the constructs -2391 to +101 and -2230 to +101, but not for the constructs with shorter promoter regions, indicating that the promoter region -2230 to -1843 contains sequence elements critical for SORD androgen induction. This region was screened for putative transcription binding DNA sequences using the TESS programme. Transcription factor search did not reveal any potential AR binding sites in the SORD 5' promoter between positions -2230 and -1843. However, several potential glucocorticoid receptor binding sequences were identified at positions -2179 to -2173, -1986 to -1980, -1974 to -1968 and -1853 to -1847 at the SORD 5' promoter. As the AR and glucocorticoid receptor can activate the same hormone response element (13) , these regions were regarded as potential androgen receptor binding sites. These potential binding sites were screened using ChIP (data not shown), and immunoprecipitation with the AR antibody was demonstrated between positions -1943 and -1824 ( Fig. 3) . Thus, the glucocorticoid receptor binding sequence at position -1853 to -1847 may serve as an androgen receptor binding site as well.
SORD protein expression in the human prostate. SORD protein was detected in a prostate sample using Western blotting. Incubation with blocking SORD protein led to the loss of specific binding in the Western blotting as expected (Fig. 4A) . The expression and localisation of SORD in the prostate was further studied immunohistochemically ( Fig. 4B-C) . The SORD antibody strongly stained the luminal epithelial cells in benign glands, but there was no staining in the prostatic stroma. In prostate cancer samples, the expression was also localised in epithelial cells. In some cases, nuclear staining was present (Fig. 4B) . The significance of this nuclear staining remains unclear, but it is likely to be unspecific staining. The immunostaining was evaluated using the criteria specified in Materials and methods to quantify the expression of SORD. In prostate cancer, there were 1 (4%), 10 (40%) and 14 (56%) samples with negative, weakly positive and strongly positive expressions, respectively. In benign prostatic glands (BPH samples and benign structures in prostate cancer samples), there were 0 (0%), 5 (33%) and 10 (67%) samples with negative, weakly positive and strongly positive expressions, respectively. In hormone naive patients (BPH patients and prostate cancer patients), there were strong expressions of SORD in benign glands in 9/13 (69.2%) cases, whereas in prostate cancer the expression was strong in 5/16 (31.2%) cases. Interestingly, in castrated patients there was strong SORD expression in all prostate cancer cases (Table II) . In prostate cancer, strong SORD expression was further detected in patients with higher Gleason patterns and higher PSA concentrations compared with patients with weak SORD expressions (Table III) . No such similarity was detected in the expression of SORD in benign glands of the same prostates (Table III) , meaning the elevated expression of SORD was connected to prostate cancer. Table II . Immunostaining of SORD in benign prostate and prostate cancer. 
The immunostaining of SORD was increased in prostate cancer patients with chemical or surgical castration as a treatment compared with hormone naive patients. Significant differences were not detected in the immunostaining at benign glands (Fisher's exact test). Table III . The association of SORD immunostaining with Gleason patterns and PSA concentrations in prostate cancer and in benign glands of prostate cancer samples. 
SORD immunostaining was significantly stronger in prostate cancer with higher Gleason patterns and higher PSA concentrations. In benign glands of prostate cancer samples, there were no differences between SORD immunostaining and Gleason patterns of the same prostates or between SORD immunostaining and PSA concentrations. Values are medians with 25th-75th percentiles. P-values are from the Mann-Whitney U test.
Discussion
During the search for novel androgen-regulated genes in prostate, we identified SORD. SORD is an enzyme that is involved in glucose metabolism, converting sorbitol to fructose using NAD(+) as a coenzyme. In the reproductive tract, SORD is believed to be involved in energy production for spermatozoa, due to the high glucose and fructose content in semen (14) . Seminal vesicles and ampuls of vas deferences are the main sources of fructose in semen (15) . SORD is widely expressed in human tissues (3) and therefore it may have other tissue-specific functions besides converting sorbitol to fructose, as fructose production may not be required in every tissue in which SORD is expressed.
To our knowledge, the hormonal regulation of SORD expression has not been described in humans. However, dexamethasone administration increases serum SORD levels in rats (16) . It is unclear whether glucocorticoid-induced elevated SORD levels in rats are a consequence of the steroid hormone up-regulated expression of SORD or liver tissue damage (16) . Here, we detected decreased expressions of SORD mRNA in the prostate after castration compared with benign prostate tissue without castration. Furthermore, SORD expression was high in prostate cancer with high Gleason patterns and high PSAs. This association was absent in benign glands of cancer samples, suggesting a cancer-specific elevated expression of SORD. The expression of SORD was also high in patients with chemical or surgical castration. The castrated prostate cancer patients had hormone refractory prostate cancer with mainly high PSAs and high Gleason scores. This supports the similar regulation of SORD and PSA in prostate cancer because the serum concentrations of androgen-regulated PSA were high and the tissue expression of SORD was high.
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is linked to prostate cancer. STAT5A/B regulates the viability of prostate cancer cells and is activated in human prostate cancer cells (17) . Patients with specific STAT3 phosphorylation had a different prognosis compared to patients without this STAT3 phosphorylation (18) . Furthermore, STAT3 is involved in the metastatic behaviour of human prostate cancer cells (19) . In the heart, the aldose reductase pathway has been demonstrated to be a key component of myocardial reperfusion injury (20) . JAK2 and STAT5 signalling induction were detected after global ischaemia. Pharmacological inhibition of sorbitol dehydrogenase blocks JAK2 and STAT5 activation in rat heart (21) . The role of SORD in regulation of the JAK-STAT pathway in the human prostate remains to be clarified, but it might be a potential physiological role for SORD in the prostate.
We have demonstrated the androgen-regulated expression of SORD in the human prostate and identified a putative androgen responsive regulatory region at the 5' promoter of SORD. The function of SORD in the prostate is unknown because the majority of fructose production seems to occur in the reproductive tract upstream of the prostate (14) . However, as the expression of SORD is regulated by androgens, it is logical to hypothesise that SORD also has a relevant function in the prostate. Furthermore, the expression of SORD was localised in the epithelial cells of both benign and malignant prostate tissue, which means that SORD is expressed in the most physiologically active cells of the prostate.
The expression of SORD is regulated by androgens in human prostate. In prostate cancer, increased immunostaining was associated with high Gleason patterns and high serum PSA concentrations. Our results suggest the need for more detailed functional characterisation of SORD in the human prostate as well as evaluation of the prognostic significance of SORD in larger clinical materials.
